Skip to main content
Caplight Logo









Refeyn

Refeyn

Private
OxfordHealthcare & Life Scienceshttps://refeyn.com/

Last Round

Series B

Apr 11, 2022

Total Funding Raised

$99.93M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Refeyn is a life sciences instrumentation company that develops, produces, and distributes mass photometry technology for the analysis of individual molecules in solution.

Sector

Healthcare & Life Sciences

Verticals

Biotech Equipment, Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Hardware Sales, Data as a Service

AI Layer

Non-AI

Keywords

mass photometrybiologics analysisprotein characterizationantibody analysislabel-free analysisbiotech instrumentationmolecular massbiosimilar characterizationgene therapy analysisanalytical workflowprotein stabilitylab equipmentbenchtop instrumentsbiotech toolsaav analysis

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Refeyn Comparables

Compare Refeyn with similar companies based on industry and business-model similarity.

Refeyn comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
NanoTemper Technologies
78%
Unchained Labs
76%
Nicoya Lifesciences Inc.
74%

Refeyn Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BApr 11, 2022
Series ANov 1, 2020
SeedMar 4, 2019
SeedJun 26, 2018

Key People

Founding team and executive leadership

Gerry Mackay

Chief Executive Officer

Executive Team

Refeyn Investors

Notable investors and investment history

Refeyn investors
InvestorRounds
Foresight Group Holdings LimitedSeries B
Horizons VenturesSeries A, Series B
Oxford Science EnterprisesSeries A, Series B, Seed
Northpond VenturesSeries A, Series B
University of OxfordSeed, Series A, Series B
Foresight Group LLPSeries A, Series B
Foresight Williams TechnologySeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 18, 2026

    Launched the MyMass instrument for sample quality assessment.

  • Nov 5, 2025

    Company has grown to over 170 employees.

Refeyn Filings

Explore SEC and related filing metadata, where available.

Refeyn filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Refeyn's valuation, stock price, and market status.

Is Refeyn a public or private company?

Refeyn is a private company.

What is the current stock price of Refeyn?

Refeyn is a private company with no public stock price. No recent secondary market data is available.

How much is Refeyn worth (valuation)?

Valuation information for Refeyn is not publicly available.

Can I buy Refeyn stock?

Refeyn shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Refeyn's last funding round?

Refeyn's most recent funding round was Series B on April 1, 2022.

Who are the main investors in Refeyn?

Key investors in Refeyn include Oxford Science Enterprises, Northpond Ventures, Foresight Williams Technology.

Will Refeyn IPO soon?

No public IPO plans have been announced for Refeyn.

How can I track Refeyn secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Refeyn's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersOxford
Employee Range143
Year Founded2018
Last FundingApr 11, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?